Navigation Links
Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
Date:2/11/2008

uccessfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this press release. Pharmacopeia undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
2. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Announces Third Quarter 2007 Financial Results
4. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
7. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
10. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
11. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced a ... use in portable vaporizers, which contains CBD, or ... cannabis, cannabidiol offers consumers a THC-free product made ... vaporizer technology. Photo - http://photos.prnewswire.com/prnh/20140711/126344 ... different compounds which are currently known, two of ...
(Date:7/11/2014)... -- Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI ), ... and Drug Administration ("FDA"), has notified the Company that ... Drug ("IND") application before granting the Company permission to ... Dr. Chris Chapman , RCP,s President, commented, "We ... When we receive the agency,s official comments and/or recommendations, ...
(Date:7/11/2014)... Research and Markets  has announced the addition of ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... needle commonly used with a syringe to inject substances ... it. A hypodermic needle is used for rapid delivery ... ingested. Hypodermic needles are broadly classified into non-safety and ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
(Date:7/13/2014)... 2014 Micro irrigation systems are mainly ... dispersal as wells as to maintain soil quality. The ... to become a dominant revenue generator for manufacturers in ... reduce resource costs has led to the adoption of ... has further caused massive demand for micro irrigation systems, ...
(Date:7/13/2014)... Fuel additives are chemicals, which are added ... kerosene, and so on, in order to enhance their ... corrosion effects caused by fuels and improving the combustion ... provide economies of scale in the long run, but, ... of the fuel products. , The various fuel additive ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 A Massachusetts ... to the cancer risks associated with power morcellators ( ... their story to federal regulators, as they presented poignant ... Food & Drug Administration (FDA) advisory panel meeting convened ... According to the Rochester Democrat and Chronicle, Dr. Hooman ...
(Date:7/13/2014)... Athletes with a certain genetic make-up are prone ... research presented today at the American Orthopaedic Society for ... marks the first of its kind investigating a genetic ... that occur after a head injury. , “We ... (GT)n genotype were four times more likely to have ...
(Date:7/13/2014)... July 13, 2014 Max International ... Chris Mullin, will be the featured guest at its ... in Puerto Rico. Attendees will learn about Max’s ... in two exhibition basketball games and perform in a ... supplier of health- and energy-boosting supplements , has recently ...
Breaking Medicine News(10 mins):Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4
... LOVELAND, Colo., Dec. 3 Heska Corporation,(Nasdaq: ... the BioWest 2007 Mature,Company Forum on December 6, ... in Denver, Colorado. The presentation is scheduled to ... http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ), About Heska, Heska Corporation ...
... UCB today announced data demonstrating,that anti-epileptic ... name,Rikelta(TM), administered as an adjunctive treatment in ... significantly reduced,seizure frequency and had a side-effect ... two Phase IIb (Abstracts C.04 and 3.218), ...
... SAN FRANCISCO, Calif., Dec. 3 Exelixis,Inc. (Nasdaq: EXEL ... and,investor briefing in conjunction with The American Society of Hematology,48th ... Monday, December 10,2007., The event will be webcast and ... http://www.exelixis.com ., Speakers:, -- Michael Morrissey, ...
... ORLANDO, Fla., Dec. 3 A new study ... depressant effects in,patients (40 years and older) with ... measured by oxygenation or abnormal breathing,events relative to ... at the 53rd International,Respiratory Congress of the American ...
... In the first survey to specifically measure hospital ... Institute (LA BioMed) researchers found few U.S. emergency rooms ... Drs. Marianne Gausche-Hill, Charles Schmitz and Roger J. Lewis ... peer-reviewed journal of the American Academy of Pediatrics. The ...
... 2007 Psychiatry researchers at Washington University School of Medicine ... alcohol dependence in young adults is associated with having a ... study reported 50 or 100 partners, and research shows ... partners you have, the more likely you,ll encounter someone with ...
Cached Medicine News:Health News:UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam 2Health News:UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam 3Health News:UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam 4Health News:UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam 5Health News:Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction With The American Society of Hematology 48th Annual Meeting 2Health News:New Study Demonstrates Ramelteon Does Not Exacerbate Respiratory Depressant Effects in Patients With Moderate-to-Severe COPD 2Health News:New Study Demonstrates Ramelteon Does Not Exacerbate Respiratory Depressant Effects in Patients With Moderate-to-Severe COPD 3Health News:New Study Demonstrates Ramelteon Does Not Exacerbate Respiratory Depressant Effects in Patients With Moderate-to-Severe COPD 4Health News:LA BioMed researchers find few emergency rooms fully equipped for pediatric patients 2Health News:Heavy drinking, conduct disorder linked to high-risk sexual behavior 2Health News:Heavy drinking, conduct disorder linked to high-risk sexual behavior 3
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only...
... and Respiratory Products, ,Westmed designs, manufacturers ... Anesthesia and Respiratory professionals. Our mission is ... the clinician's ability to deliver quality medical ... bottom line. , ,Our web site ...
... dose inhalers., ,ACE ensures prompt, effective ... Its versatile design allows it to be ... with an endotracheal airway or resuscitation bag ... also be used in conjunction with an ...
... PARI TREK™ Compact Compressor is for active ... treatments anywhere and everywhere. The compressor is ... power source optionsworldwide AC compatibility (100 to ... permit patients the freedom to take aerosol ...
Medicine Products: